Skip to main content

Carr Patricia's Form 4 filing

Jazz Pharmaceuticals plc (JAZZ) · filed Mar 8, 2024

Accession no.
0001765581-24-000038
Filed
Mar 8, 2024
Trade date
Mar 6-7, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market sales total $438.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Carr PatriciaCIK 0001784606Officer (SVP, Chief Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 6, 2024Ordinary SharesSSaleDisposed−1,236$120.85−$149,370.69,064Direct
Mar 6, 2024Ordinary SharesSSaleDisposed−700$117.51−$82,2578,364Direct
Mar 7, 2024Ordinary SharesSSaleDisposed−1,768$116.98F2−$206,820.646,596Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $116.93 to $117.00. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)